# FDA 483 - Abid H. Khan MD - July 02, 2021

Source: https://www.keypedia.com/records/483/abid-h-khan-md/55de1a21-8db7-4a79-b1e4-d7405891d6a7

> FDA 483 for Abid H. Khan MD on July 02, 2021. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Abid H. Khan MD
- Inspection Date: 2021-07-02
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Abid H. Khan MD, a clinical investigator in Ontario, CA, revealed significant deficiencies in the conduct of clinical trials. Observations included inadequate investigational drug disposition records, lacking details on dispensed quantities, lot numbers, and subject compliance. Additionally, the Principal Investigator failed to review multiple adverse event reports, including one serious adverse event, indicating a lack of proper investigation into study-related issues.

## Related Officers

- [ Director, Bioresearch Monitoring Division (West) and FDA Delegate to the OECD Working Party on GLPs](https://www.keypedia.com/people/eric-s-pittman/878b3087-615d-4e1f-9a9f-0649b46b817b)
- [investigator](https://www.keypedia.com/people/cheron-m-portee/c2cf139d-e4ce-400d-893e-bd733b3ec3a9)

Company: https://www.keypedia.com/companies/abid-h-khan-md/fed26091-5cb5-448f-8468-dc1395f2f74c

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6